RxDoctor Payments Data

Patricia Hallett, MD

Family Medicine · Trafalgar, INNPI 1194802611

Payments from drug & device makers

$400in general payments, 2019–2025

Across 27 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$82
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$79
  • AbbVie$56
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • Boehringer Ingelheim$50
  • GSK$28
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$32180%
  • Education$7920%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$400 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$107,905
Medicare patients
213
Services billed
2,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide176$211,534
OzempicSemaglutide141$179,055
JardianceEmpagliflozin158$151,093
EliquisApixaban91$105,062
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$43,023
LinzessLinaclotide30$36,081
XareltoRivaroxaban37$33,257
ProliaDenosumab18$31,207
TrulicityDulaglutide26$29,559
MyrbetriqMirabegron24$26,844
ViberziEluxadoline17$26,280
FarxigaDapagliflozin Propanediol19$24,195
JanuviaSitagliptin Phosphate18$19,578
Spiriva RespimatTiotropium Bromide22$17,623
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr35$16,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$241,093202 claims
Novo NordiskOzempic$82$179,055141 claims
Boehringer IngelheimJardiance, Spiriva Respimat$50$168,716180 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$28$75,270127 claims
AbbVieLinzess, Viberzi$56$62,36147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Trafalgar

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →